<div><p><b>Background: </b>Despite advances in understanding the pathophysiology of nonalcoholic steatohepatitis (NASH), no pharmacotherapy has been proven effective in improving outcome. Peroxisome proliferator-activated receptors (PPAR) are nuclear receptors with key role in metabolic homeostasis and inflammation and PPAR knockout mice are susceptible to development of NASH. Studies have shown protective role of PPAR-α in hepatic steatosis and inflammation and PPAR-γ as insulin sensitizers.

<div><p><b>Background:</p> </b><p>The identification of at-risk metabolic dysfunction-associated steatohepatitis (MASH) patients remains a main challenge in both clinical practice and clinical trial settings. Several non-invasive biomarkers have been developed to identify those at-risk MASH patients who would benefit from pharmacological therapy. We aimed to describe the main predictors of at-risk MASH across multiple therapeutic clinical trials.</p>

<div><p><strong><b>Background:</strong> </b>Chronic liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and viral hepatitis, contribute significantly to liver-related morbidity and mortality. Statins, commonly prescribed for dyslipidemia, have been suggested to possess hepatoprotective effects beyond their lipid-lowering properties.

<div><p><b>Background: </b>Genetic factors contribute to the risk and severity of NAFLD and fibrosis, however, the utility of genetic testing to stratify the risk for advanced fibrosis and cirrhosis among patients with type 2 diabetes mellitus (T2DM) remains poorly characterized.</p>

<div><p><b>Background: </b>Alagille syndrome (ALGS) is an inherited liver disorder dominated by high <em>γ</em>-glutamyltransferase (GGT) cholestasis. Previous studies have demonstrated limited efficacy of surgical interruption of the enterohepatic circulation in ALGS, with varying degrees of improvement in pruritus and xanthomas. Utilizing the GALA database, we sought to evaluate whether surgical biliary diversion (SBD) alters the natural history of liver disease.</p>

<div><p><b>Background: </b>Alagille syndrome (ALGS) is a rare, autosomal dominant multisystem disorder characterized by cholestasis and extrahepatic manifestations. Given the current era of ileal bile acid transporter (IBAT) inhibitor therapies that reduce serum bile acid (SBA) levels, the aim of this study was to determine whether SBA are a predictor of clinical outcomes in ALGS.</p>

<div><p><strong>Background</strong>: <span style="font-size: 11.0pt; color: windowtext;">Selgantolimod (SLGN) is an oral selective small molecule TLR8 agonist with antiviral potential that has been shown to be safe and well-tolerated in individuals with chronic hepatitis B (CHB). SLGN stimulates a robust pharmacodynamic response as measured by the detection of TLR8 pathway cytokines such as interleukin (IL)-12p40 and IL-1RA.

<div><p><b>Background:</p> </b><p>Despite liver transplant (LT) waitlist prioritization being based on model for end stage liver disease (MELD) score, situations arise when patients are not optimally represented: 1) “inactive” and 2) lower MELD due to missing MELD “recertification”. LT candidates are required to update, or “recertify”, their labs within a certain amount of time based on their MELD (e.g., MELD ≥25 requires recertification by 7 days or MELD decreases to last lower value and then to 6 if missed again).

<div><p><b>Background: </b>Alcohol-related liver disease is a major cause of liver cirrhosis and has recently emerged as the most common indication for liver transplantation. Hepatorenal syndrome (HRS)—a rapidly progressive renal failure—is a fatal complication of decompensated cirrhosis with ascites. The FDA-approved vasopressin analogue, terlipressin (terli)—in combination with albumin—is recommended to treat patients (pts) with HRS-acute kidney injury (AKI). Terli also demonstrated efficacy in the subpopulation of pts with alcohol-related hepatitis.

<div><p><b>Background: </b>Patients with primary sclerosing cholangitis (PSC) are at a 400-fold increased risk of cholangiocarcinoma (CCA), and are thus recommended to undergo annual screening with magnetic resonance cholangiopancreatography (MRCP). Unfortunately, MRCP findings are nonspecific for CCA in the setting of biliary fibrosis and screening may not confer a survival benefit. We have previously developed a new class of diagnostic tools that detect dysregulated protease activity in the tumor microenvironment.